1️⃣ BMS and Hengrui built a 13-asset bridge BMS agreed a global collaboration with Hengrui across 13 early-stage oncology, hematology and immunology programs, paying up to $950m near term and with total potential value up to $15.2bn.
💡 Why it matters BMS is using China-originated discovery as a portfolio-level option engine, while Hengrui gets validation, capital and global reach without giving up every development lever.
☕ Coffee talk The question is not whether one asset works. It is whether this becomes a repeatable China-to-global pipeline architecture.
2️⃣ Rigel bought Veppanu’s commercial problem Rigel licensed global rights to Veppanu from Arvinas and Pfizer, paying $70m upfront plus $15m on transition and up to $320m in milestones for the newly FDA-approved oral PROTAC breast cancer drug.
💡 Why it matters Arvinas and Pfizer move an approved asset into a commercial-stage hematology/oncology platform, while Rigel gets a fourth product and a sharper growth story.
☕ Coffee talk If the first approved PROTAC needs a specialist commercial home this quickly, the modality win still needs a market-access proof point.
3️⃣ Boehringer bought an Immunitas inflammation option Boehringer licensed worldwide rights to Immunitas’ preclinical first-in-class antibody program for chronic inflammatory disease, with milestones up to €407.5m plus royalties.
💡 Why it matters It is a small upfront-to-large-option deal, but it gives Boehringer another immunology shot before human data and gives Immunitas a development partner with scale.
☕ Coffee talk Preclinical immunology options are cheap until the biology starts asking for proof. Boehringer is buying optionality, not validation.